Tal Medical reporting that it did not achieve the primary endpoint in its RAPID trial in major depressive disorder (MDD) is disappointing. Depression affects millions of adults globally and is the leading cause of suicide. PureTech owns 54.2% of Tal Medical and it currently represents 10.5% of PureTech’s $291.7m valuation of its growth stage companies. Tal Medical will report additional data from two other trials in MDD in H2 2016. All the data will be reviewed over the next six months and we ex ....
02 Jun 2016
Disappointing data from Tal Medical
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Disappointing data from Tal Medical
PureTech Health PLC (PRTC:LON) | 214 1.1 0.2% | Mkt Cap: 576.9m
- Published:
02 Jun 2016 -
Author:
Sheena Berry -
Pages:
4
Tal Medical reporting that it did not achieve the primary endpoint in its RAPID trial in major depressive disorder (MDD) is disappointing. Depression affects millions of adults globally and is the leading cause of suicide. PureTech owns 54.2% of Tal Medical and it currently represents 10.5% of PureTech’s $291.7m valuation of its growth stage companies. Tal Medical will report additional data from two other trials in MDD in H2 2016. All the data will be reviewed over the next six months and we ex ....